GSA Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-61,578
| Closed | -$2.78M | – | 1684 |
|
|
2025
Q3 | $2.78M | Buy |
61,578
+14,260
| +30% | +$666K | 0.23% | 29 |
|
|
2025
Q2 | $2.19M | Buy |
47,318
+40,605
| +605% | +$1.99M | 0.15% | 104 |
|
|
2025
Q1 | $409K | Buy |
+6,713
| New | +$391K | 0.04% | 933 |
|
|
2024
Q4 | – | Sell |
-7,671
| Closed | -$397K | – | 1619 |
|
|
2024
Q3 | $397K | Sell |
7,671
-2,318
| -23% | -$109K | 0.03% | 1063 |
|
|
2024
Q2 | $415K | Buy |
+9,989
| New | +$447K | 0.03% | 1079 |
|
|
2024
Q1 | – | Sell |
-66,286
| Closed | -$3.4M | – | 1618 |
|
|
2023
Q4 | $3.4M | Buy |
66,286
+2,600
| +4% | +$136K | 0.29% | 20 |
|
|
2023
Q3 | $3.7M | Buy |
+63,686
| New | +$3.9M | 0.32% | 10 |
|
|
2022
Q3 | – | Sell |
-27,910
| Closed | -$2.15M | – | 1527 |
|
|
2022
Q2 | $2.15M | Buy |
27,910
+25,005
| +861% | +$1.9M | 0.32% | 10 |
|
|
2022
Q1 | $212K | Sell |
2,905
-8,512
| -75% | -$572K | 0.03% | 1145 |
|
|
2021
Q4 | $712K | Buy |
11,417
+4,732
| +71% | +$278K | 0.09% | 375 |
|
|
2021
Q3 | $396K | Buy |
+6,685
| New | +$440K | 0.04% | 840 |
|
|
2020
Q1 | – | Sell |
-12,329
| Closed | -$791K | – | 1079 |
|
|
2019
Q4 | $791K | Sell |
12,329
-5,121
| -29% | -$293K | 0.09% | 338 |
|
|
2019
Q3 | $885K | Sell |
17,450
-20,178
| -54% | -$948K | 0.12% | 216 |
|
|
2019
Q2 | $1.71M | Sell |
37,628
-3,843
| -9% | -$179K | 0.19% | 69 |
|
|
2019
Q1 | $1.98M | Buy |
41,471
+21,385
| +106% | +$1.07M | 0.2% | 64 |
|
|
2018
Q4 | $1.04M | Sell |
20,086
-33,927
| -63% | -$1.82M | 0.12% | 201 |
|
|
2018
Q3 | $3.35M | Buy |
54,013
+33,513
| +163% | +$1.99M | 0.19% | 67 |
|
|
2018
Q2 | $1.13M | Sell |
20,500
-50,564
| -71% | -$2.73M | 0.06% | 673 |
|
|
2018
Q1 | $4.5M | Buy |
71,064
+2,484
| +4% | +$160K | 0.24% | 34 |
|
|
2017
Q4 | $4.2M | Buy |
68,580
+58,842
| +604% | +$3.68M | 0.26% | 31 |
|
|
2017
Q3 | $621K | Buy |
9,738
+848
| +10% | +$49.5K | 0.04% | 833 |
|
|
2017
Q2 | $495K | Sell |
8,890
-76,462
| -90% | -$4.16M | 0.03% | 1011 |
|
|
2017
Q1 | $4.64M | Buy |
85,352
+61,725
| +261% | +$3.39M | 0.25% | 23 |
|
|
2016
Q4 | $1.38M | Sell |
23,627
-186,122
| -89% | -$10.2M | 0.08% | 373 |
|
|
2016
Q3 | $11.3M | Buy |
209,749
+185,773
| +775% | +$11.9M | 0.61% | 4 |
|
|
2016
Q2 | $1.76M | Buy |
23,976
+11,848
| +98% | +$837K | 0.1% | 295 |
|
|
2016
Q1 | $775K | Sell |
12,128
-10,796
| -47% | -$681K | 0.05% | 705 |
|
|
2015
Q4 | $1.58M | Buy |
22,924
+5,365
| +31% | +$355K | 0.08% | 382 |
|
|
2015
Q3 | $1.04M | Buy |
+17,559
| New | +$1.11M | 0.05% | 597 |
|
|
2015
Q2 | – | Sell |
-77,977
| Closed | -$5.03M | – | 1951 |
|
|
2015
Q1 | $5.03M | Buy |
77,977
+54,882
| +238% | +$3.44M | 0.2% | 52 |
|
|
2014
Q4 | $1.36M | Buy |
23,095
+3,082
| +15% | +$174K | 0.1% | 293 |
|
|
2014
Q3 | $1.02M | Sell |
20,013
-3,030
| -13% | -$151K | 0.05% | 469 |
|
|
2014
Q2 | $1.12M | Sell |
23,043
-89,634
| -80% | -$4.42M | 0.05% | 610 |
|
|
2014
Q1 | $5.85M | Buy |
112,677
+103,945
| +1,190% | +$5.53M | 0.42% | 30 |
|
|
2013
Q4 | $464K | Buy |
+8,732
| New | +$445K | 0.04% | 905 |
|
|
2013
Q3 | – | Sell |
-60,903
| Closed | -$2.72M | – | 1562 |
|
|
2013
Q2 | $2.72M | Buy |
+60,903
| New | +$2.64M | 0.32% | 29 |
|
Other funds holding BMY
GSA Capital Partners's BMY Position: Q4 2025 in Review
GSA Capital Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 61,578 shares — an estimated $2.78M sold.
GSA Capital Partners first reported a position in BMY in Q2 2013 and held it in 36 quarters. The position peaked at $11.3M in Q3 2016. 2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.
- GSA Capital Partners reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
- GSA Capital Partners sold 61,578 Bristol-Myers Squibb shares in Q4 2025, an estimated $2.78M.
- GSA Capital Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 36 quarters.
- GSA Capital Partners's Bristol-Myers Squibb position peaked at $11.3M in Q3 2016.
- 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.
Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.